Sarcoma: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• KRAS 10
• TP53 1
• PD-1 19
• PD-L1 9
• PI3K 0
• AKT 0
• NTRK 2
• mTOR 0
• STAT3 0
• MAPK 0
• CTNNB1 0
• MDM2 2
• BRAF 3
• MYC 0
• RAS 3
• JNK 0
• VEGF 3
• ERK 0
• ALK 2
• B7-H3 10
• STING 1
• CDK4/6 3
• JAK 1
• PARP 4
• YAP 0
• EGFR 1
• IDH 2
• FGFR 2
• HER2 5
• MEK 2
• CTLA-4 5
• NRAS 0
• HIF-1 0
• PTEN 0
• EZH2 0
• GPX4 0
• PPAR 0
• NF1 5
• AMPK 0
• GPC3 5
• METTL3 1
• PDGFR 3
• ABL1 0
• COX-2 0
• ROS1 2
• AXL 0
• CD47 0
• CDKN2A 0
• IL-15 4
• MMP-9 0
• PRAME 1
• PSMA 0
• RET 0
• BCL-2 0
• BRCA2 1
• CD19 2
• CXCR4 0
• FLT3 0
• FTO 0
• HDAC 0

EU-13 is a filter, not a ranking: it only narrows the list.

17 of 17+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue Sarcoma

  NCT03116529· University of Maryland, Baltimore· Updated 5 Nov 2026

  “Limited Accrual”Registry text, quoted unchanged. Source

• Suspended

  Olomorasib + Pembrolizumab KRAS G12C Mutant, PD-L1 TPS 1-49% Locally Advanced or Metastatic NSCLC

  NCT07639242· UNC Lineberger Comprehensive Cancer Center· Updated 28 Aug 2026

  “Administrative”Registry text, quoted unchanged. Source

• Terminated

  A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers

  NCT04260802· Ocellaris Pharma, Inc.· Updated 12 Jan 2026

  “Business Decision”Registry text, quoted unchanged. Source

• Terminated

  A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

  NCT02936102· Novartis Pharmaceuticals· Updated 14 Nov 2025

  “The early termination was based on a business decision that FAZ053 would no longer be formulated and was not a consequence of any safety concern.”Registry text, quoted unchanged. Source

• Terminated

  Study on TSR-042 in Advanced Clear Cell Sarcoma

  NCT04274023· Italian Sarcoma Group· Updated 1 Feb 2024

  “Difficulty of enrollment”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS

  NCT06008093· AstraZeneca· Source

• A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

  NCT06345729· Merck Sharp & Dohme LLC· Source

• Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV

  NCT04902443· National Cancer Institute (NCI)· Source

• A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

  NCT06066138· National Cancer Institute (NCI)· Source

• KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

  NCT07252739· Merck Sharp & Dohme LLC· Source

• Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma

  NCT04458922· National Cancer Institute (NCI)· Source

• Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas

  NCT04242238· Memorial Sloan Kettering Cancer Center· Source

• A phase II study to assess the efficacy of the anti-PD-L1 antibody atezolizumab (MPDL3280A) administered with stereotactic ablative radiotherapy (SABR) in patients with metastatic tumours (SABR-PDL1)

  2024-515678-29-00· Institut Gustave Roussy· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 40
• Organoids 10
• Mendelian Randomization Analysis 2
• CRISPR-Cas Systems 10
• Gene Expression Profiling 99
• Sequence Analysis, RNA 21
• Whole Genome Sequencing 4
• Exome Sequencing 14
• Proteomics 31
• Metabolomics 7
• Mass Spectrometry 5
• Flow Cytometry 52
• Immunohistochemistry 184
• Liquid Biopsy 12
• Circulating Tumor DNA 19
• Xenograft Model Antitumor Assays 152
• Positron-Emission Tomography 19
• Magnetic Resonance Imaging 194
• Machine Learning 28
• Deep Learning 16
• Cohort Studies 30
• Genome-Wide Association Study 2

See which targets of this disease your abstract mentions, and go to the people working on them.